Detalhe da pesquisa
1.
Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab.
Ann Oncol
; 28(1): 103-109, 2017 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28177480
2.
Prediction of local and metastatic recurrence in solitary fibrous tumor: construction of a risk calculator in a multicenter cohort from the French Sarcoma Group (FSG) database.
Ann Oncol
; 28(8): 1979-1987, 2017 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28838212
3.
Clinical validation of a prognostic tool in a population of outpatients treated for incurable cancer undergoing anticancer therapy: PRONOPALL study.
Ann Oncol
; 28(7): 1612-1617, 2017 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28472235
4.
Fracture incidence after 3 years of aromatase inhibitor therapy.
Ann Oncol
; 25(4): 843-847, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24608193
5.
High prevalence of vertebral fractures in women with breast cancer starting aromatase inhibitor therapy.
Ann Oncol
; 23(5): 1151-1156, 2012 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-21903604
6.
Factors associated with enrolment in clinical trials among women with early-stage breast cancer.
ESMO Open
; 7(3): 100513, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35724624
7.
Patterns of care and outcomes of 417 patients with METAstatic SYNovial sarcoma (METASYN): real-life data from the French Sarcoma Group (FSG).
ESMO Open
; 7(2): 100402, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35202953
8.
[HIV sleeping, sleeping...]. / VIH qui dort, qui dort...
Rev Med Suisse
; 11(489): 1863-4, 2015 Oct 07.
Artigo
em Francês
| MEDLINE | ID: mdl-26638518
9.
PREMIUM: A French prospective multicenter observational study of factors impacting on efficacy and compliance to cetuximab treatment in first-line KRAS wild-type metastatic colorectal cancer.
PLoS One
; 15(12): e0243997, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33347495
10.
Osteoporosis treatment and 10 years' oestrogen receptor+ breast cancer outcome in postmenopausal women treated with aromatase inhibitors.
Eur J Cancer
; 101: 87-94, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30036740
11.
[Black holes in white matter]. / Des trous noirs dans la matière blanche.
Rev Med Suisse
; 8(357): 1935-6, 2012 Oct 10.
Artigo
em Francês
| MEDLINE | ID: mdl-23130425
12.
[Keep a cool head!]. / Gardons la tête froide!
Rev Med Suisse
; 7(293): 969, 2011 May 04.
Artigo
em Francês
| MEDLINE | ID: mdl-21634149
13.
Distinct chromosomal alterations associated with TP53 status of LoVo cells under PALA selective pressure: a parallel with cytogenetic pathways of colorectal cancers.
Oncogene
; 18(3): 775-81, 1999 Jan 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-9989828
14.
Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study.
J Clin Oncol
; 10(11): 1795-801, 1992 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-1403060
15.
Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I-II study of weekly cisplatin/interferon alfa-2a.
J Clin Oncol
; 14(3): 878-85, 1996 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-8622036
16.
Phase I/II study of escalating doses of vinorelbine in combination with oxaliplatin in patients with advanced non-small-cell lung cancer.
J Clin Oncol
; 19(2): 458-63, 2001 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-11208839
17.
[The devastating destiny of negative results]. / Le désolant destin des résultats négatifs.
Rev Med Suisse
; 6(250): 1094-5, 2010 May 26.
Artigo
em Francês
| MEDLINE | ID: mdl-20564871
18.
Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC). ATTIT. Association pour le Traitement des Tumeurs Intra Thoraciques.
Eur J Cancer
; 34(7): 1124-7, 1998 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-9849465
19.
Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer.
Eur J Cancer
; 33(9): 1400-6, 1997 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-9337681
20.
Higher doses of alpha-interferon do not increase the activity of the weekly cisplatin-interferon combination in advanced malignant mesothelioma.
Eur J Cancer
; 33(11): 1900-2, 1997 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-9470855